NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
1.300
0.00 (0.00%)
Nov 21, 2024, 11:29 AM EST - Market open
NextCure Employees
NextCure had 82 employees as of December 31, 2023. The number of employees decreased by 17 or -17.17% compared to the previous year.
Employees
82
Change (1Y)
-17
Growth (1Y)
-17.17%
Revenue / Employee
n/a
Profits / Employee
-$713,634
Market Cap
36.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
RAPT Therapeutics | 131 |
Barinthus Biotherapeutics | 130 |
Beyond Air | 107 |
Carisma Therapeutics | 107 |
Lumos Pharma | 33 |
Incannex Healthcare | 9 |
Eterna Therapeutics | 8 |
Dyadic International | 7 |
NXTC News
- 2 days ago - Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - GlobeNewsWire
- 13 days ago - NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 15 days ago - NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 6 weeks ago - NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 2 months ago - NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 - GlobeNewsWire
- 5 months ago - NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 6 months ago - NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 - GlobeNewsWire
- 7 months ago - NextCure Provides Business Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire